These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 15243520

  • 1. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.
    Querfeld C, Rosen ST, Guitart J, Rademaker A, Fung BB, Posten W, Kuzel TM.
    J Am Acad Dermatol; 2004 Jul; 51(1):25-32. PubMed ID: 15243520
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
    Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC, Worldwide Bexarotene Study Group.
    Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
    Singh F, Lebwohl MG.
    J Am Acad Dermatol; 2004 Oct; 51(4):570-3. PubMed ID: 15389192
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
    Kannangara AP, Levitan D, Fleischer AB.
    J Dermatolog Treat; 2009 Oct; 20(3):169-76. PubMed ID: 19016373
    [Abstract] [Full Text] [Related]

  • 8. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
    Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, Brown PH.
    Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):467-74. PubMed ID: 12010861
    [Abstract] [Full Text] [Related]

  • 9. Treatment of cutaneous T-cell lymphoma with retinoids.
    Zhang C, Duvic M.
    Dermatol Ther; 2006 May; 19(5):264-71. PubMed ID: 17014481
    [Abstract] [Full Text] [Related]

  • 10. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
    Rigas JR, Dragnev KH.
    Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250
    [Abstract] [Full Text] [Related]

  • 11. Central hypothyroidism associated with retinoid X receptor-selective ligands.
    Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M.
    N Engl J Med; 1999 Apr 08; 340(14):1075-9. PubMed ID: 10194237
    [Abstract] [Full Text] [Related]

  • 12. Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides.
    Pileri A, Delfino C, Grandi V, Pimpinelli N.
    Immunotherapy; 2013 Apr 08; 5(4):427-33. PubMed ID: 23557425
    [Abstract] [Full Text] [Related]

  • 13. Combination treatment modalities in cutaneous T-cell lymphoma (CTCL).
    Guitart J.
    Semin Oncol; 2006 Feb 08; 33(1 Suppl 3):S17-20. PubMed ID: 16516671
    [Abstract] [Full Text] [Related]

  • 14. Folliculotropic mycosis fungoides responding to bexarotene gel.
    Walling HW, Swick BL, Gerami P, Scupham RK.
    J Drugs Dermatol; 2008 Feb 08; 7(2):169-71. PubMed ID: 18335654
    [Abstract] [Full Text] [Related]

  • 15. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma.
    Wollina U, Dummer R, Brockmeyer NH, Konrad H, Busch JO, Kaatz M, Knopf B, Koch HJ, Hauschild A.
    Cancer; 2003 Sep 01; 98(5):993-1001. PubMed ID: 12942567
    [Abstract] [Full Text] [Related]

  • 16. Current treatment of Cutaneous T-Cell Lymphoma.
    Duvic M.
    Dermatol Online J; 2001 Feb 01; 7(1):3. PubMed ID: 11328624
    [Abstract] [Full Text] [Related]

  • 17. Bexarotene: new preparation. Cutaneous lymphoma: too many adverse effects.
    Prescrire Int; 2004 Jun 01; 13(71):94-7. PubMed ID: 15233146
    [Abstract] [Full Text] [Related]

  • 18. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
    Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M.
    J Clin Oncol; 2007 Jul 20; 25(21):3109-15. PubMed ID: 17577020
    [Abstract] [Full Text] [Related]

  • 19. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
    Bouwhuis SA, Davis MD, el-Azhary RA, McEvoy MT, Gibson LE, Knudsen JM, Kist JM, Pittelkow MR.
    J Am Acad Dermatol; 2005 Jun 20; 52(6):991-6. PubMed ID: 15928617
    [Abstract] [Full Text] [Related]

  • 20. A Phase I study of LGD1069 in adults with advanced cancer.
    Rizvi NA, Marshall JL, Dahut W, Ness E, Truglia JA, Loewen G, Gill GM, Ulm EH, Geiser R, Jaunakais D, Hawkins MJ.
    Clin Cancer Res; 1999 Jul 20; 5(7):1658-64. PubMed ID: 10430065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.